SRR1473733
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.397
- KRAS_SIGNALING_DN+0.385
- SPERMATOGENESIS+0.358
- MYOGENESIS+0.271
- INFLAMMATORY_RESPONSE+0.237
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.204
- ANGIOGENESIS+0.185
- ALLOGRAFT_REJECTION+0.170
- COAGULATION+0.138
- HEDGEHOG_SIGNALING+0.125
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- MYC_TARGETS_V1-0.468
- G2M_CHECKPOINT-0.466
- PROTEIN_SECRETION-0.464
- E2F_TARGETS-0.446
- UNFOLDED_PROTEIN_RESPONSE-0.429
- DNA_REPAIR-0.417
- MITOTIC_SPINDLE-0.407
- WNT_BETA_CATENIN_SIGNALING-0.366
- MTORC1_SIGNALING-0.325
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NFRXNAFE | ganglioneuroblastoma | — | 0.918 |
| 2 | SRR1397073 | GTEX | — | 0.917 |
| 3 | SRR1456294 | GTEX | — | 0.901 |
| 4 | SRR12202435 | — | — | 0.900 |
| 5 | SRR662091 | GTEX | — | 0.899 |
| 6 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.895 |
| 7 | SRR1420215 | GTEX | — | 0.890 |
| 8 | SRR1085662 | GTEX | — | 0.890 |
| 9 | SRR1416754 | GTEX | — | 0.888 |
| 10 | SRR1458810 | GTEX | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.397 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.385 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.358 | Inavolisib | — uncovered |
| MYOGENESIS | 0.271 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.237 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.204 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.185 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| COAGULATION | 0.138 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.125 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.123 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.123 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.115 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.107 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.082 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.067 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.042 | Inavolisib | — uncovered |
| COMPLEMENT | 0.038 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.027 | Inavolisib | — uncovered |